Vadaparampil S.T., Malo T.L., Kahn J.A., Salmon D.A., Lee H.H., Quinn G.P. et al. Physicians’ human papillomavirus vaccine recommendations. 2009 and 2011. Am. J. Prev. Med. 2014; 46(1): 80-4.
Monsonego J. HPV testing in prevention of cervical cancer: practices and current trends. Am. Biol. Clin. (Paris). 2013; 71: 27-32.
Shah K.V. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma. J. Infect. Dis. 2013.
Ngamkham J., Homcha-Aim P., Boonmark K., Phansri T., Swangvaree S.S. Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. Asian Pac. J. Cancer Prev. 2013; 14(4): 2355-9.
Fernandes J., Carvalho M., de Fernandes T., Ara@ujo J., Azevedo P., Azevedo J., Meissner R. Prevalence of human papillomavirus type 58 in women with or without cervical lesions in northeast Brazil. Ann. Med. Hlth Sci. Res. 20l3; 3(4): 504-10.
Priebe A.M. 2012 cervical cancer screening guidelines and the future role of HPV testing. Clin. Onstet. Gynecol. 2013; 56(1): 44-50.
Brinkman J.A., Hughes S.H., Stone P., Caffrey A.S., Mucerspach L.I., Koman L.D. et al. Therapeutic vaccination for HPV induced cervical cancers. Dis. Markers. 2007; 23(4): 337-52.
Hung C.F., Wu T.C., Monie A., Roden R. Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol. Rev. 2008; 222: 43-69.
Sharma R.K., Srivastava A.K., Yolcu E.S., MacLeod K.J., Schabowsky R.-H., Madireddi S., Shirwan H. SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine. 2010; 28(36): 5794-802.
Cid-Arregui A. Therapeutic vaccines against human papillomavirus and cervical cancer. Open Viro. J. 2009; 3: 37-83.
Marx U., Sandig V. Drug Testing in Vitro. Breakthroighs and Trends in Cell Culture Technology. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA; 2007.
Wood C.E., Chen Z., Cline J.M., Miller B.E., Burk R.D. Characterization and experimental transmission of an oncogenic papillomavirus in female macaques. J. Virol. 2007; 81(12): 6339-45.
Christensen N.D., Kreider J.W. Animal models of papillomavirus. In: Handbook of Animal Models of Infection / Eds. O. Zak, M. A. Sande. London: Academic Press, 1999.
Suckow M.A., Stevens K.A., Wilson R.P. The Laboratory Rabbit, Guinea Pig, Hamster, and Other Rodents (American College of Laboratory Animal Medicine). Academic Press; 2012.
Christensen N.D. Cottontail rabbit papillomavirus (CRPV) model system to test antiviral and immunotherapeutic strategies. Antivir. Chem. Chemother. 2005; 16(6): 355-62.
Leachman S.A., Tigelaar R.E., Shlyankevich M.,, Slade M.D., Irwin M., Chang E. et al. Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: effects on papilloma formation and regression in the cottontail rabbit papillomavirus-rabbit model. J. Virol. 2000; 74(18): 8700-8.
Ito Y., Evans C.A. Induction of tumors in domestic rabbits with nucleic acid preparations from partially purified shope papilloma virus and from extracts of the papillomas of domestic and cottontail rabbits. J. Exp. Med. 1961; 114(4): 485-500.
Salmon J., Ramoz N., Cassonnet P., Orth G., Breitburd F. A cottontail rabbit papillomavirus strain (CRPVb) with strikingly divergent E6 and E7 oncoproteins: An insight in the evolution of papillomaviruses. Virology. 1997; 235(2): 228-34.
Nasseri M., Meyers C., Wettstein F.O. Genetic analysis of CRPV pathogenesis: the L1 open reading frame is dispensable for cellular transformation but is required for papilloma formation. Virology. 1989; 170(1): 321-5.
Christensen N.D., Cladel N.M., Reed C.A., Han R. Rabbit oral papillomavirus complete genome sequence and immunity following genital infection. Virology. 2000; 269(2): 451-61.
Cladel N.M., Hu J., Balogh K.K., Christensen N.D. Differences in methodology, but not differences in viral strain, account for variable experimental outcomes in laboratories utilizing the cottontail rabbit papillomavirus model. J. Virol. Meth. 2010; 165(1): 36-41.
Maglennon G.A., McIntosh P., Doorbar J. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology. 2011; 414(2): 153-63.
Embers M.E., Budgeon L.R., Pickel M., Christensen N.D. Protective immunity to rabbit ora1 and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol. 2002; 76(19): 9798-805.
Zhang P., Nouri M., Brandsma J.L., Iftner T., Steinberg B.M. Induction of E6/E7 expression in cottontail rabbit papillomavirus latency following UV activation. Virology. 1999; 263(2): 388-94.
Hu J., Cladel N.M., Budgeon L.R., Christensen N.D. Characterization of three rabbit oral papillomavirus oncogenes. Virology. 2004; 325(1): 48-55.
Peh W.L., Mlddleton K., Chrlstensen N., Nlcholls P., Egawa K., Sotlar K. et al. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J. Virol. 2002; 76(20): 10401-16.
Mejia A.F., Culp T.D., Cladel N.M., Balogh K.K., Budgeon L.R., Buck C.B., Christensen N.D. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J. Virol. 2006; 80(24): 12393-7.
Schellenbacher C., Roden R., Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J. Virol. 2009; 83(19): 10085-95.